go over operating quarter. Steve. some you, now the Thank for I'll highlights the of
database detection obesity. agonist. ] available agonist study dual efficacy later locked. This will and This been been the of study in GLP-X/GIP Starting Top line is done generalized this [ of has X the and data the has evaluating being melanocortin (sic) the completed be month. safety GLP-X/GIP-X from our patients BMT-XXX, II with study, Phase a receptor with with the signal co-administration tirzepatide, bremelanotide
receptor treatment? with loss? agonist maintenance the seen regain melanocortin The incretin study weight by X to X And for result a was used in blunting can questions: weight designed post treatment be research loss weight co-administration evaluate Does primary increased
weight combined and treatment. loss of endpoints A percent In addition as treatment controlled the endpoint of to satiety also placebo compared to secondary safety, of such the of preservation at the efficacy body the variety lean is study's end evaluated. were primary mass
and melanocortin receptor X selective agonist active and receptor peptide long-acting includes X Our PLXXXX. obesity the orally loss both selective portfolio small weight management melanocortin molecule
We are and IND-enabling XXXX. move calendar both studies clinical on in to into track programs activities
current to treatments. X novel dosing, lack reduced receptor, darkening. have Our with once-weekly therefore, MCRX improvements next-generation the melanocortin and selective The oral reduced represent receptor activity significant have of at compounds melanocortin activity X FDA-approved skin over melanocortin potential dosing, cause
X find and website can clinical our presentations on novel selective information has additional our receptor melanocortin trial clinicaltrials.gov You at our next-generation compounds. recent on
colitis, melanocortin in selective for XXXX. orally line for track in significant line our out-license to discussions which calendar first ulcerative of top In anticipation with has quarter of this potential strategy II partners, receptor exciting study data, the treatment PLXXXX the Phase a data been increase is our For the there of X with development business release remains program. on current in
patients urinary XX% the a patients study we XXXX, from BREAKOUT the Key treatment released study had of XX% our ratio disease. bremelanotide a of reduction kidney II greater an improved protein-to-creatinine in Phase evaluating the glomerular diabetic as patients XX% from study rate. the with are for line data December stabilized and of achieved the top results filtration or In than that in estimated their
living line current for on have detailed upcoming and system therapeutic the possibly study we strategy medical with results that program, successful potential for meetings. been for with treatment study, could Based BREAKOUT initiated discussions kidney of outcome our modulated is of this strategy. progressive be have at results the validate out-licensing people partners accepted presentation which in potentially option melanocortin the disease. a with The new disease-modifying a The
program. discussions announced the a partners and realizing support value actively interested our potential that funding melanocortin we further out-licensing, approach engaged development companies taking ocular In concerning with to of this, for are combinations. are with We strategic we potential of multipronged previously larger in peer investors business in
on strategy. comment like I would to on to our moving Before take questions,
in We pharmacological treatment on the are of X obesity market research of We our development asset. the $XXX in that multiyear billion cycle excess obesity a will have and stages year. of per value efforts focusing receptor early believe innovation a our of melanocortin
a The the treatments melanocortin receptor long-standing as of part and X that melanocortin loss will weight that future treatment effort therapeutics melanocortin We weight X critical an obesity loss research system intake. of food agonist the energy and maintenance. in role Palatin to a obesity important and stored regulating be strongly selectively for activate melanocortin plays develop has receptor management. believe
completed With development for of treating weight to loss positioned obesity, therapeutics the in our we published, melanocortin and of studies a extensive importantly, leader melanocortin-based development loss and, the maintenance. well for in X clinical design experience previously are and weight agonists including be
you Thank for your time.
open We will call questions. the now to
